Expression of Chemokine CCL28 in Ulcerative Colitis Patients
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Ulcerative colitis (UC) is an inflammatory bowel disease for which new serological markers are required. The purpose of this study was to assess the role of the mucosaassociated epithelial chemokine CCL28 in UC. Methods: The study included 50 patients; of these, 25 were patients with UC, and 25 were healthy controls. The levels of serum CCL28 were analyzed using enzyme-linked immunosorbent assay. CCL28 expression was analyzed by immunohistochemistry (IHC) in 15 representative colon tissues biopsied based on disease activity (UC patients with severe activity, five samples; UC patients with mild activity, five samples; healthy controls, five samples). Results: The serum CCL28 levels were remarkably higher (p<0.05) in patients with UC (median, 235.7 pg/mL; IQR, 63.8 to 117.2 pg/mL) than in healthy controls (median, 48.9, pg/mL; IQR, 35.9 to 42.0 pg/mL). However, there was no significant difference in serum CCL28 according to disease extent or activity. In contrast, IHC analysis revealed a significant difference in CCL28 consistent with disease status, disease extent, and disease activity. Conclusions: CCL28 could be useful for diagnosing UC. However, further validations of CCL28 on disease activity and severity are needed.
Abstract
Background/Aims: Ulcerative colitis (UC) is an inflammatory bowel disease for which new serological markers are required. The purpose of this study was to assess the role of the mucosaassociated epithelial chemokine CCL28 in UC. Methods: The study included 50 patients; of these, 25 were patients with UC, and 25 were healthy controls. The levels of serum CCL28 were analyzed using enzyme-linked immunosorbent assay. CCL28 expression was analyzed by immunohistochemistry (IHC) in 15 representative colon tissues biopsied based on disease activity (UC patients with severe activity, five samples; UC patients with mild activity, five samples; healthy controls, five samples). Results: The serum CCL28 levels were remarkably higher (p<0.05) in patients with UC (median, 235.7 pg/mL; IQR, 63.8 to 117.2 pg/mL) than in healthy controls (median, 48.9, pg/mL; IQR, 35.9 to 42.0 pg/mL). However, there was no significant difference in serum CCL28 according to disease extent or activity. In contrast, IHC analysis revealed a significant difference in CCL28 consistent with disease status, disease extent, and disease activity. Conclusions: CCL28 could be useful for diagnosing UC. However, further validations of CCL28 on disease activity and severity are needed.
참고문헌 (36)
- Xiong N, "CCR10 and its ligands in regulation of epithelial immunity and diseases", Protein Cell, 3, pp.571~580 (2012)
- Delves PJ, "The immune system : first of two parts", N Engl J Med, 343, pp.37~49 (2000)
- Delves PJ, "The immune system : second of two parts", N Engl J Med, 343, pp.108~117 (2000)
- McIntyre TM, "Cell-cell interactions : leukocyte-endothelial interactions", Curr Opin Hematol, 10, pp.150~158 (2003)
- Charo IF, "The many roles of chemokines and chemokine receptors in inflammation", N Engl J Med, 354, pp.610~621 (2006)
- Cyster JG, "Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs", Annu Rev Immunol, 23, pp.127~159 (2005)
- Gerard C, "Chemokines and disease", Nat Immunol, 2, pp.108~115 (2001)
- Eksteen B, "Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR10", J Immunol, 177, pp.593~603 (2006)
- Mohan T, "CCL28 chemokine : an anchoring point bridging innate and adaptive immunity", Int Immunopharmacol, 51, pp.165~170 (2017)
- Kim BG, "Expression of human T cell-activating CXC chemokines in inflammatory bowel disease", Intest Res, 2, pp.58~64 (2004)
- Mora JR, "Homing imprinting and immunomodulation in the gut : role of dendritic cells and retinoids", Inflamm Bowel Dis, 14, pp.275~289 (2008)
- von Andrian UH, "T-cell function and migration. Two sides of the same coin", N Engl J Med, 343, pp.1020~1034 (2000)
- Baumgart DC, "Inflammatory bowel disease : cause and immunobiology", Lancet, 369, pp.1627~1640 (2007)
- Matsuo K, "CCL28-deficient mice have reduced IgA antibody-secreting cells and an altered microbiota in the colon", J Immunol, 200, pp.800~809 (2018)
- Rashidiani S, "The chemokine CCL28is elevated in the serum of patients with celiac disease and decreased after treatment", Am J Clin Exp Immunol, 6, pp.60~65 (2017)
- Zwicker S, "Systemic chemokine levels with"gut-specific"vedolizumab in patients with inflammatory bowel disease-a pilot study", Int J Mol Sci, 18, pp.1827~ (2017)
- 최창환, "궤양성 대장염 진단 가이드라인", 대한소화기학회지, 53(3), pp.145~160 (2009), 대한소화기학회
- Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis", N Engl J Med, 353, pp.2462~2476 (2005)
- Yoon JH, "Plasma CC-chemokine ligand 28 level is correlated with hematopoietic stem cells in human cord blood", Transfusion, 55, pp.1008~1012 (2015)
- Ohuchida K, "The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target", Clin Cancer Res, 11, pp.7785~7793 (2005)
- Kuna AT, "Serological markers of inflammatory bowel disease", Biochem Med(Zagreb), 23, pp.28~42 (2013)
- Barta Z, "Seroreactivity against Saccharomyces cerevisiae in patients with Crohn’s disease and celiac disease", World J Gastroenterol, 9, pp.2308~2312 (2003)
- Rieder F, "Serum anti-glycan antibodies predict complicated Crohn’s disease behavior : a cohort study", Inflamm Bowel Dis, 16, pp.1367~1375 (2010)
- Rieder F, "Association of the novel serologic anti-glycan antibodies anti-laminarin and antichitin with complicated Crohn’s disease behavior", Inflamm Bowel Dis, 16, pp.263~274 (2010)
- Simondi D, "Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease", Inflamm Bowel Dis, 14, pp.645~651 (2008)
- Ferrante M, "New serological markers in inflammatory bowel disease are associated with complicated disease behaviour", Gut, 56, pp.1394~1403 (2007)
- Oudkerk Pool M, "Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis : a correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment", Gut, 34, pp.46~50 (1993)
- Høie O, "Serological markers are associated with disease course in ulcerative colitis : a study in an unselected population-based cohort followed for 10 years", J Crohns Colitis, 2, pp.114~122 (2008)
- Vecchi M, "Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis : sensitivity, specificity and recognition of putative antigens", Digestion, 55, pp.34~39 (1994)
- Sandborn WJ, "Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis : results of a pilot study", Mayo Clin Proc, 71, pp.431~436 (1996)
- Prideaux L, "Serological antibodies in inflammatory bowel disease : a systematic review", Inflamm Bowel Dis, 18, pp.1340~1355 (2012)
- Bossuyt X, "Serologic markers in inflammatory bowel disease", Clin Chem, 52, pp.171~181 (2006)
- Reumaux D, "Anti-neutrophil cytoplasmic auto-antibodies(ANCA)in ulcerative colitis(UC) : no relationship with disease activity", Inflamm Bowel Dis, 6, pp.270~274 (2000)
- Ogawa H, "Regulated production of the chemokine CCL28 in human colon epithelium", Am J Physiol Gastrointest Liver Physiol, 287, pp.G1062~ (2004)
- Aziz N, "Stability of cytokines, chemokines and soluble activation markers in unprocessed blood stored under different conditions", Cytokine, 84, pp.17~24 (2016)
- Hansson M, "CCL28 is increased in human Helicobacter pylori-induced gastritis and mediates recruitment of gastric immunoglobulin Asecreting cells", Infect Immun, 76, pp.3304~3311 (2008)